Cytek Biosciences Inc. (CTKB) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $6.30 (+2.61% 1D, market cap $818.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTKB ranks #607 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.7% realized swing band)
Altman Z-Score 4.76 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CTKB currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.28) and Max Pain ($6.62) forces dealer call-delta covering toward $6.87.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cytek Biosciences Inc. (CTKB) surged +2.61% to $6.30, trading at 99% of its 52-week range ($3.31 – $6.34). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conference
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytek Biosciences is back in focus as fair value estimates have shifted from about US$5.69 to roughly US$6.17 per share, reflecting a modest reset in price targets. Analysts cluster around this updated range with a mix o
FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter of 2026 after market
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CTKB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CTKB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytek Biosciences Inc. (CTKB) ranks #607 by composite RQD confidence (41/100, grade D-) and #384 by equity capitalization ($818.9M). Within this direct 5-issuer industry benchmark cohort, CTKB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CTKB at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTKB
ACTIVE
Cytek Biosciences Inc. | D- | 41/100 | — | 51.8% | -12.7% | +2.61% | $818.9M | Benchmark Subject |
| PACB Pacific Biosciences of California Inc. | D- | 37/100 | — | 28.6% | -35.0% | +2.47% | $901.4M | /pacb-vs-ctkb → |
| NAUT Nautilus Biotechnology Inc. | D- | 41/100 | — | — | -35.0% | -2.18% | $399.9M | /naut-vs-ctkb → |
| ALMR Alamar Biosciences Inc. | D | 48/100 | — | — | — | -0.76% | $2.36B | /almr-vs-ctkb → |
| LAB Standard BioTools Inc. | D- | 41/100 | — | 49.9% | -28.7% | +0.49% | $244.7M | /lab-vs-ctkb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytek Biosciences Inc. (CTKB) reported GAAP revenue of $201.5M (+0.5% vs. FY2024 revenue of $200.5M , and +4.4% cumulative change since FY2023) , GAAP net income of -$66.5M, operating cash flow of -$4.7M, and free cash flow of -$8.8M (-140.1% YoY). On the balance sheet, CTKB closed FY2025 with $461.5M in total assets against $0 in total debt (Altman Z-Score: 4.76, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $201.5M | -$66.5M | -$4.7M | -$8.8M | $461.5M | — |
| FY2024 (FY) | 2024-12-31 | $200.5M | -$6.0M | $25.4M | $21.9M | $499.5M | — |
| FY2023 (FY) | 2023-12-31 | $193.0M | -$12.1M | $5.3M | $5.3M | — | — |
As of 2026-11-01, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $6.30 (+2.61% 1D, market cap $818.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTKB ranks #607 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CTKB last traded at $6.30 (+2.61% on volume of 1,914,850 shares), positioning the stock +19.32% above its 50-day simple moving average ($5.28) and +35.48% above its 200-day simple moving average ($4.65). Across its 52-week range of $3.31 to $6.34, CTKB sits at the 98.7% percentile with a 14-day RSI of 65.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.7% ($5.56 to $7.04).
Why CTKB Stock surged +2.61% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.